Compare · NVS vs VERA
NVS vs VERA
Side-by-side comparison of Novartis AG (NVS) and Vera Therapeutics Inc. (VERA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and VERA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $305.27B, about 120.1x VERA ($2.54B).
- VERA has hit the wire 10 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 18 for VERA).
- Company
- Novartis AG
- Vera Therapeutics Inc.
- Price
- -
- -
- Market cap
- $305.27B
- $2.54B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 10
- Recent ratings
- 25
- 18
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Vera Therapeutics Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
Latest VERA
- Amendment: PRESIDENT AND CEO Fordyce Marshall exercised 46,250 shares at a strike of $2.90 and sold $1,956,187 worth of shares (46,250 units at $42.30) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: PRESIDENT AND CEO Fordyce Marshall exercised 18,500 shares at a strike of $2.90 and sold $701,769 worth of shares (18,500 units at $37.93) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: PRESIDENT AND CEO Fordyce Marshall exercised 18,500 shares at a strike of $2.90 and sold $679,747 worth of shares (18,500 units at $36.74) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Vera Therapeutics Inc.
- Vera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
- Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form SCHEDULE 13G filed by Vera Therapeutics Inc.
- Chief Regulatory Officer Boman Nancy Lee was granted 44,987 shares (SEC Form 4)
- SEC Form 3 filed by new insider Boman Nancy Lee